Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 4 clinical trials
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

This phase I trial studies the side effects and best dose of MDM2 inhibitor KRT-232 in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent

karnofsky performance status
bevacizumab
bilateral tubal ligation
malignant brain tumor
carcinoma in situ
  • 127 views
  • 01 Aug, 2021
  • 3 locations
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

This phase I trial studies the side effects and best dose of MDM2 Inhibitor KRT-232 when given together with carfilzomib, lenalidomide, and dexamethasone in treating patient with multiple

serum calcium
dexamethasone
plasmacytoma
graft versus host disease
carfilzomib
  • 27 views
  • 15 May, 2021
  • 4 locations
KRT-232 (AMG-232) and Decitabine in Treating Patients With Relapsed Refractory or Newly-Diagnosed Acute Myeloid Leukemia

This phase Ib trial studies the side effects and best dose of murine double minute chromosome 2 (MDM2) inhibitor KRT-232 (AMG-232) when given together with decitabine in treating patients with

hydroxyurea
secondary acute myeloid leukemia
refractory acute myeloid leukemia (aml)
decitabine
blast cells
  • 170 views
  • 26 May, 2021
  • 4 locations
MDM2 Inhibitor AMG-232 (KRT-232) and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 (KRT-232) and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 (KRT-232) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 (KRT-232) and …

platelet count
metastasis
cancer
neutrophil count
cancer chemotherapy
  • 253 views
  • 01 Aug, 2021
  • 35 locations